L
Laura D. Locati
Researcher at University of Milan
Publications - 192
Citations - 6143
Laura D. Locati is an academic researcher from University of Milan. The author has contributed to research in topics: Cancer & Head and neck cancer. The author has an hindex of 35, co-authored 170 publications receiving 4810 citations. Previous affiliations of Laura D. Locati include University of Gothenburg.
Papers
More filters
Journal ArticleDOI
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact
Laura D. Locati,Federica Perrone,Barbara Cortelazzi,Cristiana Bergamini,Paolo Bossi,Enrico Civelli,Carlo Morosi,S. Lo Vullo,Martina Imbimbo,Pasquale Quattrone,G.P. Dagrada,Roberta Granata,Carlo Resteghini,Aurora Mirabile,Salvatore Alfieri,Ester Orlandi,Luigi Mariani,Gabriella Saibene,S. Pilotti,Lisa Licitra +19 more
TL;DR: Sorafenib is the first anti-angiogenic agent to demonstrate activity in RMSGC patients, particularly in some histotypes such as HG-MEC, SDC and adenocarcinoma, NOS.
Journal ArticleDOI
Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer
Lisa Licitra,Laura D. Locati,R. Cavina,I. Garassino,Franco Mattavelli,Natalia Pizzi,Pasquale Quattrone,P. Valagussa,Luca Gianni,G. Bonadonna,Carlo L. Solero,Giulio Cantù +11 more
TL;DR: PFL is active in paranasal cancer and patients who attain a pathological complete remission have a favorable prognosis, and primary chemotherapy combined with surgery-sparing treatment approaches deserves further investigation.
Journal ArticleDOI
A complete remission with androgen-deprivation therapy in a recurrent androgen receptor-expressing adenocarcinoma of the parotid gland.
Journal ArticleDOI
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982).
C.M.L. van Herpen,Laura D. Locati,Jan Buter,José Thomas,Jan Bogaerts,Denis Lacombe,P.H.M. de Mulder,Ahmad Awada,Lisa Licitra,Jacques Bernier,Jan B. Vermorken +10 more
TL;DR: It is concluded that gemcitabine is not an active drug in ACC and is well tolerated by most patients.
Journal ArticleDOI
Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life
Laura D. Locati,Donata Galbiati,Giuseppina Calareso,Salvatore Alfieri,Susanne Singer,Stefano Cavalieri,Cristiana Bergamini,Paolo Bossi,Ester Orlandi,Carlo Resteghini,Francesca Platini,Roberta Granata,Pasquale Quattrone,Moela Mancinelli,Luigi Mariani,Salvatore Lo Vullo,Lisa Licitra +16 more
TL;DR: The treatment of patients with recurrent and/or metastatic (R/M) salivary gland adenoid cystic carcinoma (ACC) remains an unmet need.